Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kanwaljit Mahal

Urology Lubbock, TX Medical Doctor

NPI 1447361092 CMS profile 337428

6102 82Nd St, Suite 5, Lubbock, TX 79424

Open in the dashboard

General payments

$17,766

332 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kanwaljit Mahal of Lubbock, TX is reported in the CMS Open Payments database as having received $17,766 across 332 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,438 51
2024 General $2,199 41
2023 General $1,769 49
2022 General $3,794 53
2021 General $2,322 54
2020 General $1,830 31
2019 General $1,414 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kanwaljit Mahal
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Kanwaljit Mahal were reported at $4,438. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Kanwaljit Mahal Urology median Middle half National median
2019 $1,414 $480 $147–$1,201 $163
2020 $1,830 $246 $87–$645 $114
2021 $2,322 $358 $111–$1,000 $132
2022 $3,794 $476 $143–$1,263 $149
2023 $1,769 $560 $168–$1,461 $160
2024 $2,199 $563 $170–$1,464 $164
2025 $4,438 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $5,161 23 payments
  2. Boston Scientific Corporation $3,720 31 payments
  3. PROCEPT BioRobotics Corporation $1,876 22 payments
  4. Janssen Biotech, Inc. $992 43 payments
  5. Astellas Pharma US Inc $922 52 payments
  6. Urogen Pharma, Inc. $657 11 payments
  7. Sumitomo Pharma America, Inc. $552 25 payments
  8. AbbVie, Inc. $352 14 payments
  9. Teleflex LLC $339 5 payments
  10. Medtronic, Inc. $320 5 payments
  11. Other $2,874 101 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,551 307 payments
  2. Travel and Lodging $5,622 22 payments
  3. Education $1,593 3 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $3,661 22 payments
  2. AdVance XP $2,463 10 payments
  3. DA VINCI SP $1,500 1 payment
  4. AQUABEAM ROBOTIC SYSTEM $1,379 17 payments
  5. ERLEADA $890 42 payments
  6. XTANDI $747 44 payments
  7. JELMYTO $640 10 payments
  8. GEMTESA $623 29 payments
  9. MYRBETRIQ $597 38 payments
  10. AQUABEAM SYSTEM $459 4 payments
  11. Other $5,495 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,153

Median for Urology: 1,053

Drug cost

$348,725

Median for Urology: $101,464

Branded share of claims

25.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 11 $153,106
Myrbetriq Mirabegron Brand 157 $107,795
Gemtesa Vibegron Brand 66 $38,364
Mirabegron Er Mirabegron Brand 34 $21,033
Tamsulosin Hcl Generic 748 $8,176
Finasteride Generic 474 $5,412
Testosterone Generic 30 $2,981
Silodosin Generic 28 $2,541
Oxybutynin Chloride Er Oxybutynin Chloride Brand 130 $1,794
Trimethoprim Generic 30 $1,521

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$297,284

Of which drugs: $87,683

Medicare patients

632

Average age 75

Services billed

9,453

135 women, 497 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 44%
Diabetes 39%
Chronic kidney disease 26%
Cancer 26%
Atrial fibrillation 22%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 18 99 $13,676
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 57 68 $137

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ERLEADA
  • Janssen Biotech, Inc. $216
$216 — —
JELMYTO
  • UROGEN PHARMA, INC. $86
$86 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $72
$72 66 —
BOTOX
  • AbbVie, Inc. $68
$68 — —
AKEEGA
  • Janssen Biotech, Inc. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

332 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record